Literature DB >> 19304916

Body tumor CT perfusion protocols: optimization of acquisition scan parameters in a rat tumor model.

Alessia Tognolini1, Rachel Schor-Bardach, Oleg S Pianykh, Carol J Wilcox, Vassilios Raptopoulos, S Nahum Goldberg.   

Abstract

PURPOSE: To evaluate the effects of total scanning time (TST), interscan delay (ISD), inclusion of image at peak vascular enhancement (IPVE), and selection of the input function vessel on the accuracy of tumor blood flow (BF) calculation with computed tomography (CT) in an animal model.
MATERIALS AND METHODS: All animal protocols and experiments were approved by the institutional animal care and use committee prior to study initiation. After injection of 0.2 or 0.4 mL of iodinated contrast material, six rats with mammary adenocarcinoma (three tumors each) were scanned in the axial mode for 5 minutes with 1-second ISD (reference scan), 2.5-mm section thickness, 2.5-mm interval, pitch of 1.3, 120 kV, 240 mA, and 0.5-second rotation time. A total of 126 dynamic data sets were created with commercial software by varying TST and ISD, including or excluding the IPVE, and using the aorta or inferior vena cava (IVC) as the input function. Comparative analyses were used to test for significant differences (t test, Wilcoxon signed rank test). Regression analysis was performed to assess the relationship between attenuation of the input function vessel and BF.
RESULTS: No significant difference was observed (P > .05) when TST was as short as 30 seconds (range, 20-23 mL/100 g). In sequences performed with an ISD longer than 8 seconds, BF was significantly elevated (P < .01). Inclusion of the IPVE eliminated this difference (P > .10). Use of the IVC as the input function resulted in significantly higher BF (P < .02), with a correlation between peak attenuation and BF (R(2) = 0.43).
CONCLUSION: To reduce radiation dose in tumor perfusion with CT, TST can be reduced without causing significant changes in BF calculation in an animal model. Scanning the aortic reference with peak contrast enhancement reduces variability sufficiently to allow for longer ISDs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19304916      PMCID: PMC2687528          DOI: 10.1148/radiol.2511080410

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  24 in total

Review 1.  Perfusion CT: a worthwhile enhancement?

Authors:  K A Miles; M R Griffiths
Journal:  Br J Radiol       Date:  2003-04       Impact factor: 3.039

2.  Staging of non-small-cell lung cancer with integrated PET and CT.

Authors:  Kenneth A Miles
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

3.  Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism.

Authors:  Ukihide Tateishi; Hiroshi Nishihara; Eriko Tsukamoto; Toshiaki Morikawa; Nagara Tamaki; Kazuo Miyasaka
Journal:  J Comput Assist Tomogr       Date:  2002 Mar-Apr       Impact factor: 1.826

4.  First-pass measurements of regional blood flow with external detectors.

Authors:  N A Mullani; K L Gould
Journal:  J Nucl Med       Date:  1983-07       Impact factor: 10.057

5.  Derivation of gamma variate indicator dilution function from simple convective dispersion model of blood flow.

Authors:  M D Harpen; M L Lecklitner
Journal:  Med Phys       Date:  1984 Sep-Oct       Impact factor: 4.071

6.  A physiologic model of capillary-tissue exchange for dynamic contrast-enhanced imaging of tumor microcirculation.

Authors:  T S Koh; L H Cheong; Z Hou; Y C Soh
Journal:  IEEE Trans Biomed Eng       Date:  2003-02       Impact factor: 4.538

7.  Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data.

Authors:  Yoshito Tsushima; Shintaro Funabasama; Jun Aoki; Shigeru Sanada; Keigo Endo
Journal:  Acad Radiol       Date:  2004-02       Impact factor: 3.173

8.  Dynamic perfusion CT: optimizing the temporal resolution and contrast volume for calculation of perfusion CT parameters in stroke patients.

Authors:  Max Wintermark; Wade S Smith; Nerissa U Ko; Marcel Quist; Pierre Schnyder; William P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

9.  Correlation between tumor blood flow assessed by perfusion CT and effect of neoadjuvant therapy in advanced esophageal cancers.

Authors:  Yoichi Makari; Takushi Yasuda; Yuichiro Doki; Hiroshi Miyata; Yoshiyuki Fujiwara; Shuji Takiguchi; Jin Matsuyama; Makoto Yamasaki; Takafumi Hirao; Mitsuhiro Koyama Koyama; Hironobu Nakamuara; Morito Monden
Journal:  J Surg Oncol       Date:  2007-09-01       Impact factor: 3.454

10.  Assessment of the reproducibility of postprocessing dynamic CT perfusion data.

Authors:  David Fiorella; Joseph Heiserman; Erin Prenger; Shahram Partovi
Journal:  AJNR Am J Neuroradiol       Date:  2004-01       Impact factor: 3.825

View more
  4 in total

1.  Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT.

Authors:  P-G Qiao; H-T Zhang; J Zhou; M Li; J-L Ma; N Tian; X-D Xing; G-J Li
Journal:  Clin Transl Oncol       Date:  2015-08-05       Impact factor: 3.405

2.  Reduced time CT perfusion acquisitions are sufficient to measure the permeability surface area product with a deconvolution method.

Authors:  Francesco Giuseppe Mazzei; Luca Volterrani; Susanna Guerrini; Nevada Cioffi Squitieri; Eleonora Sani; Gloria Bettini; Chiara Pozzessere; Maria Antonietta Mazzei
Journal:  Biomed Res Int       Date:  2014-08-12       Impact factor: 3.411

3.  Assessment of hemodynamics in a rat model of liver cirrhosis with precancerous lesions using multislice spiral CT perfusion imaging.

Authors:  Guolin Ma; Rongjie Bai; Huijie Jiang; Xuejia Hao; Zaisheng Ling; Kefeng Li
Journal:  Biomed Res Int       Date:  2013-06-20       Impact factor: 3.411

Review 4.  Pushing CT and MR imaging to the molecular level for studying the "omics": current challenges and advancements.

Authors:  Hsuan-Ming Huang; Yi-Yu Shih
Journal:  Biomed Res Int       Date:  2014-03-13       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.